Two New Drugs Offer Hope for Pancreatic Cancer Time MagazineRevolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial CNBCFor Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option statnews.com
Investors back Sonire with $18M Axios
Nevada mom Haleigh Knight faked cancer diagnosis to scam more than $20K from victims: ‘She’s a sociopath’ New York Post
Finally, Real Progress Against Pancreatic Cancer Bloomberg.com
Former radio host battling stage-four pancreatic cancer WSAV-TV
Phil Garner, Three-Time MLB All-Star, Dies at 76 After Pancreatic Cancer Diagnosis People.com
My wife died from cancer. This is what I wish I’d known as her carer The Telegraph
Justice catches up with shameless Vegas mother who spewed lies and faked pancreatic cancer diagnosis for cash Daily Mail
Opinion | How Ben Sasse Is Living Now That He Is Dying The New York Times
Pancreatic cancer - Symptoms and causes Mayo Clinic
New Drug Doubles One-Year Survival in Pancreatic Cancer Trial Northwestern University
First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know Pancreatic Cancer Action Network
Daraxonrasib Shows Significant OS Benefit in Metastatic Pancreatic Cancer Targeted Oncology
Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill statnews.com
Daraxonrasib Yields Significant Survival Advantages vs Chemotherapy in Metastatic Pancreatic Cancer OncLive
Combination therapy doubles one-year survival in pancreatic cancer trial Drug Discovery News
New pancreatic cancer drug Elraglusib, created at Northwestern Medicine, helps patients live longer: Dr. Deva Mahalingam ABC7 Chicago
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer BioSpace
Daraxonrasib Shows "Unprecedented" Survival in Pretreated Pancreatic Cancer CancerNetwork
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial Nature
Emerging Strategies to Overcome Resistance in Pancreatic Cancer Targeted Oncology
Revolution rises 40% as pancreatic cancer drug doubles survival BioSpace
Gallagher on How Nurses Support Patient Goals After Initial Diagnosis of Pancreatic Cancer OncLive
PanCAN Statement on Positive Overall Survival Results from Revolution Medicines Phase III Trial Pancreatic Cancer Action Network
Q&A: Honoring Rita, One Step at a Time Pancreatic Cancer Action Network
Revolution pancreatic cancer drug nearly doubles survival in key trial BioPharma Dive
Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial Fierce Biotech
New targeted therapy gives hope to pancreatic cancer patients and families WGN-TV
Revolution Medicines' pancreatic cancer drug cuts risk of death by 60% vs. chemo CNBC
Phenotypic profiling in pancreatic cancer: promise meets practical limits ESMO Daily Reporter
Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer CNBC
Yago Garitaonaindia: Phase 3 Data in Metastatic Pancreatic Cancer Demonstrates Survival Improvement Oncodaily
Overcoming the “Impossible”: Immunotherapy Resistance in Pancreatic Cancer CancerNetwork
Northwestern study shows promise for new pancreatic cancer drug | ChicagoLIVE FOX 32 Chicago
Ashish Manne: New Pancreatic Cancer Data on Daraxonrasib Signals Potential Survival Advantage Oncodaily
This Experimental Drug Could Be a Game Changer for Pancreatic Cancer Gizmodo
Revolution Medicines Stock Is Soaring 39%. Here’s Why. Barron's
Blockage of cuproplasia inhibits pancreatic tumour-associated neutrophils infiltration through TRAF6/STAT3/CCL2 pathway Nature
Video New pill could help pancreatic cancer patients live longer, study shows abcnews.com
Daraxonrasib Improves Survival in Metastatic Pancreatic Cancer Cure Today